Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
C-glycosides
FDA
SGLT2 inhibitors
Type 2 diabetes mellitus
anti-T2DM
glucosuria
Journal
Mini reviews in medicinal chemistry
ISSN: 1875-5607
Titre abrégé: Mini Rev Med Chem
Pays: Netherlands
ID NLM: 101094212
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
04
2021
revised:
09
06
2021
accepted:
16
06
2021
pubmed:
7
8
2021
medline:
13
4
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
Type 2 diabetes mellitus (T2DM) is one of the most serious and prevalent diseases worldwide. In the last decade, type 2 sodium-glucose cotransporter inhibitors (iSGLT2) were approved as alternative drugs for the pharmacological treatment of T2DM. The anti-hyperglycemic mechanism of action of these drugs involves glycosuria. In addition, SGLT2 inhibitors cause beneficial effects such as weight loss, a decrease in blood pressure, and others. This review aimed to describe the origin of SGLT2 inhibitors and analyze their recent development in preclinical and clinical trials. In 2013, the FDA approved SGLT2 inhibitors as a new alternative for the treatment of T2DM. These drugs have shown good tolerance with few adverse effects in clinical trials. Additionally, new potential anti-T2DM agents based on iSGLT2 (O-, C-, and N-glucosides) have exhibited a favorable profile in preclinical evaluations, making them candidates for advanced clinical trials. The clinical results of SGLT2 inhibitors show the importance of this drug class as new anti-T2DM agents with a potential dual effect. Additionally, the preclinical results of SGLT2 inhibitors favor the design and development of more selective new agents. However, several adverse effects could be a potential risk for patients.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes mellitus (T2DM) is one of the most serious and prevalent diseases worldwide. In the last decade, type 2 sodium-glucose cotransporter inhibitors (iSGLT2) were approved as alternative drugs for the pharmacological treatment of T2DM. The anti-hyperglycemic mechanism of action of these drugs involves glycosuria. In addition, SGLT2 inhibitors cause beneficial effects such as weight loss, a decrease in blood pressure, and others.
OBJECTIVE
OBJECTIVE
This review aimed to describe the origin of SGLT2 inhibitors and analyze their recent development in preclinical and clinical trials.
RESULTS
RESULTS
In 2013, the FDA approved SGLT2 inhibitors as a new alternative for the treatment of T2DM. These drugs have shown good tolerance with few adverse effects in clinical trials. Additionally, new potential anti-T2DM agents based on iSGLT2 (O-, C-, and N-glucosides) have exhibited a favorable profile in preclinical evaluations, making them candidates for advanced clinical trials.
CONCLUSION
CONCLUSIONS
The clinical results of SGLT2 inhibitors show the importance of this drug class as new anti-T2DM agents with a potential dual effect. Additionally, the preclinical results of SGLT2 inhibitors favor the design and development of more selective new agents. However, several adverse effects could be a potential risk for patients.
Identifiants
pubmed: 34353256
pii: MRMC-EPUB-117076
doi: 10.2174/1389557521666210805112416
doi:
Substances chimiques
Benzhydryl Compounds
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Sodium
9NEZ333N27
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-599Subventions
Organisme : Secretaria de Investigacion y Posgrado del Instituto Politécnico Nacional
ID : SIP-20200050
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.